Purpose: Immediate initiation of antiretroviral treatment following HIV infection is a cornerstone of the current HIV 'universal test and treat' approach. Delayed progress along the HIV care continuum is thus framed as a major stumbling block in effective HIV epidemic control. Through examining the HIV care trajectories of people diagnosed with HIV in Shinyanga Region, Tanzania, we offer a critical interrogation of the HIV care continuum.
Methods: Data are drawn from a social science study on the uptake of a 'treat all' model of HIV prevention and care conducted from 2018 to 2019. Methods included interviews with participants who tested positive (n = 30) and interviews (n = 25) with health staff involved in the testing campaigns.
Findings: Exploring individuals' care trajectories, we found that most participants followed pathways to care that do not easily align with the current emphasis on rapid, linear progress from testing to treatment initiation. Instead, participants' trajectories from diagnosis to treatment happened on a different, non-linear time scale mediated through social relations and diverse communities of care. We thus conceptualize five pathways of linkage to care - virtuous/immediate, delayed testing, repeat testing, negotiated, and 'failed'.
Conclusion: Based on our findings we propose a community-centered HIV care continuum that exposes moments of potential connection with or rupture from the health system and centers the importance of social support structures and forms of relational labor involving broader communities of care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.socscimed.2023.116317 | DOI Listing |
J Family Med Prim Care
December 2024
Department of HIV and Blood Borne Viruses, Milton Keynes University Hospital, NHS Foundation Trust, Milton Keynes, UK.
We report a case of a 49-year-old female with a history of HIV infection for 12 years. The patient had excellent compliance with antiretroviral medications, raltegravir 400 mg twice daily and truvada once daily for HIV. Over the years, she maintained an undetectable viral load with a CD4+ count >200 cells/μL.
View Article and Find Full Text PDFJ Family Med Prim Care
December 2024
Department of Community Medicine, Mahatma Gandhi Medical College, Jaipur, Rajasthan, India.
Background: India shares 2/3 of global TB burden. MDR and HIV coinfections are the main obstacle in achieving the successful TB control because it decrease the therapy effect.
Objective: To analyze the long-term trends of incidence of tuberculosis cases and identify any differences between actual and projected cases after the COVID-19 pandemic.
J Family Med Prim Care
December 2024
Department of Preventive and Social Medicine, Shaheed Nirmal Mahto Medical College and Hospital, Dhanbad, Jharkhand, India.
Background: Integrated Counselling and Testing Centre (ICTC) diagnose HIV and STIs early, modifies behavior, reduces vulnerability, and data helps in understanding transmission. Despite having low HIV prevalence, Jharkhand is vulnerable. Post Covid19, HIV has increased.
View Article and Find Full Text PDFJ Family Med Prim Care
December 2024
Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
Background: Previous studies have found that people with low participation in social activities and living alone were prone to have risky sexual behaviors, while people with high participation in social activities were less prone to have risky sexual behaviors. Based on the above assumptions, we conducted an analysis on elderly population's social networks and human immunodeficiency virus (HIV) risky behaviors in China. In the survey study, considering the sensitivity of sexual behavior, HIV risk behavior of the elderly population is more difficult to measure, so the intermediate variable of HIV perceptions was used instead of the sexual behavioral variable.
View Article and Find Full Text PDFOpen Forum Infect Dis
January 2025
College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Background: The BASE study (NCT03998176), a phase 4, 48-week (W), single-arm, prospective trial, revealed that the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV and substance use disorders (PWH/SUD) was safe and effective without emergent antiretroviral resistance despite incomplete adherence. Here, we present the W96 results.
Methods: A retrospective analysis of all participants enrolled in the BASE study was completed from W48 to W96.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!